Radium-223 for the treatment of castration-resistant prostate cancer
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in p...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ |
| id |
pubmed-4445785 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-44457852015-06-08 Radium-223 for the treatment of castration-resistant prostate cancer El-Amm, Joelle Aragon-Ching, Jeanny B Review The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients with mCRPC with bone metastases. Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the advantage of minimal myelosuppression. The landmark Phase III ALSYMPCA trial demonstrated that, in addition to providing bone-related palliation, radium-223 can also prolong overall survival in patients with mCRPC with bone metastases in the absence of visceral metastases and in the absence of lymphadenopathy greater than 3 cm. Ongoing trials will further elucidate its use in sequence or combination with other available therapies for mCRPC. Dove Medical Press 2015-05-18 /pmc/articles/PMC4445785/ /pubmed/26056474 http://dx.doi.org/10.2147/OTT.S44291 Text en © 2015 El-Amm and Aragon-Ching. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
El-Amm, Joelle Aragon-Ching, Jeanny B |
| spellingShingle |
El-Amm, Joelle Aragon-Ching, Jeanny B Radium-223 for the treatment of castration-resistant prostate cancer |
| author_facet |
El-Amm, Joelle Aragon-Ching, Jeanny B |
| author_sort |
El-Amm, Joelle |
| title |
Radium-223 for the treatment of castration-resistant prostate cancer |
| title_short |
Radium-223 for the treatment of castration-resistant prostate cancer |
| title_full |
Radium-223 for the treatment of castration-resistant prostate cancer |
| title_fullStr |
Radium-223 for the treatment of castration-resistant prostate cancer |
| title_full_unstemmed |
Radium-223 for the treatment of castration-resistant prostate cancer |
| title_sort |
radium-223 for the treatment of castration-resistant prostate cancer |
| description |
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients with mCRPC with bone metastases. Radium-223 delivers cytotoxic radiation to the sites of bone metastases and offers the advantage of minimal myelosuppression. The landmark Phase III ALSYMPCA trial demonstrated that, in addition to providing bone-related palliation, radium-223 can also prolong overall survival in patients with mCRPC with bone metastases in the absence of visceral metastases and in the absence of lymphadenopathy greater than 3 cm. Ongoing trials will further elucidate its use in sequence or combination with other available therapies for mCRPC. |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/ |
| _version_ |
1613228293983567872 |